

The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR) outlines a coordinated plan for new vaccines that provide effective and long lasting protection against future variants and viruses.

The persistent threat of coronaviruses

Over the past 20 years, three dangerous coronaviruses have jumped from animals to humans.

- 2003 SARS, one in ten infections fatal
- 2012 MERS, three in ten infections fatal
- 2019 COVID-19 (SARS-CoV-2), lower fatality risk but easier to spread resulting in over 6.6 million deaths worldwide by the end of 2022

Thousands of coronaviruses circulate in animals, with continual risk of spillover to humans.

New coronavirus in the future could be both highly transmissible and highly lethal.

The Coronavirus Vaccines R&D Roadmap

- **Energizes and organizes** a global agenda for next-generation coronavirus vaccines.
- **Builds on scientific** advances and partnerships that produced the first **COVID-19 vaccines.**

Roadmap goals



Durable vaccines that protect against new variants

Long-lasting protection against severe disease and death from a wide range of coronaviruses.

でい)

Vaccines for future coronavirus threats Prepare vaccines now with broad

protection against new variants and future coronaviruses.



Globally accessible Easier to manufacture, store, and use anywhere.

Challenges with existing vaccines



New variants evade immunity



Inequities in global availability and access



Diminished benefit against new variants



Inadequate vaccine uptake, particularly with new boosters

The roadmap provides a clear strategy that encompasses the multiple areas of research needed for long lasting and broadly protective vaccines.

A coordinated strategy will galvanize research and investments to accelerate vaccine development.

How the Roadmap sets goals with timelines:

Identifies challenges, sets goals and timelines for progress.


Addresses R&D in five key areas:



Vaccinology



Animal and human infection models





Funded by

BILL& MELINDA



The findings and conclusions contained within are those of the authors and do not necessarily reflect the positions or policies of the Bill & Melinda Gates Foundation and The Rockefeller Foundation